A survey found that dermatologists have more confidence in diagnosing, managing, and their personal knowledge of permanent chemotherapy-induced alopecia compared with clinicians who practice in oncology or primary care/internal medicine.
A single-institution study is able to reproduce results of previous studies on the use of a scalp cooling system to prevent chemotherapy-induced hair loss in patients with breast cancer receiving anthracycline and/or taxane-based therapies.
A study results presented at the 2018 ONS Annual Congress demonstrated that incorporating scalp cooling with the Dignicap device prior to chemotherapy for breast cancer may reduce treatment-related alopecia.
Risk of chemotherapy-induced hair loss common to breast cancer therapy may be reduced with the use of scalp-cooling device.
A new system appears efficacious in preventing chemotherapy-related alopecia in women with breast cancer, according to a study presented at SABCS 2016.
Inducing vasoconstriction in the scalp of patients with breast cancer undergoing chemotherapy effectively reduces the amount of drug that reaches the hair follicles and hair-cell metabolism, minimizing one of the most dreaded side effects of treatment.
A new project is working on improving scalp cooling technology that prevents hair loss in cancer patients.
Can vitamins or supplements help address hair loss caused by cancer therapy?
A patient’s self image can reduce his or her coping abilities and can be significantly impacted by this distressing side effect.
